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Abstract
Therapeutic regimens for the COVID- 19 pandemics remain unmet. In this line, re-
purposing of existing drugs against known or predicted SARS- CoV- 2 protein actions 
have been advanced, while natural products have also been tested. Here, we pro-
pose that p- cymene, a natural monoterpene, can act as a potential novel agent for the 
treatment of SARS- CoV- 2- induced COVID- 19 and other RNA- virus- induced diseases 
(influenza, rabies, Ebola). We show by extensive molecular simulations that SARS- 
CoV- 2 C- terminal structured domain contains a nuclear localization signal (NLS), like 
SARS- CoV, on which p- cymene binds with low micromolar affinity, impairing nuclear 
translocation of this protein and inhibiting viral replication, as verified by preliminary 
in vitro experiments. A similar mechanism may occur in other RNA- viruses (influ-
enza, rabies and Ebola), also verified in vitro for influenza, by interaction of p- cymene 
with viral nucleoproteins, and structural modification of their NLS site, weakening 
its interaction with importin A. This common mechanism of action renders therefore 
2 of 12  |     PANAGIOTOPOULOS eT AL.
1  |  INTRODUC TION
An unforeseen International effort led to the identification of the 
cause of the novel COVID- 19 disease (the SARS- CoV- 2 virus) and 
the detailed analysis of its genome,1 a few months since its out-
break. Sustained academic and industrial effort led to the pro-
duction of successful vaccines,2– 4 or vaccine candidates,5,6 based 
on different technologies (see Ref. [7] for an exhaustive analysis 
of technologies and report of all candidate vaccines). However, 
an efficient dedicated therapy has not yet been advanced. Actual 
therapeutic approaches comprise antibodies or antibody cock-
tails against the spike protein of the virus, employed for host 
cell entry.8,9 In addition, a number of alternative viral targets are 
actually explored as potential drug candidates.10– 13 Indeed, the 
viral genome, one of the longest found in RNA viruses, codes 
for a number of distinct proteins, comprising a small (pp1a) and 
large (pp1ab) polyprotein (gene ORF1ab), while other genes (S, 
E, M, and N) encode the structural proteins Spike, Envelope, 
Membrane, and Nucleocapsid, respectively. Ten open reading 
frames (ORF1– ORF10) encode accessory proteins with specu-
lated functionality.14 A number of these proteins have been in-
vestigated as potential drug targets. Finally, the in- depth analysis 
of viral biology and its interaction with cellular mechanisms led to 
repurposing of a number of drugs, with the notable recent para-
digm of colchicine.15,16
The nucleocapsid (N) protein is one of the most important 
SARS- CoV- 2 proteins.17 A detailed analysis of this protein has 
been recently published.18 The authors report that N- protein 
plays an important role in viral replication, assembly, and immune 
regulation. Although the full crystal structure of the protein has 
not yet been resolved, they report that SARS- CoV- 2 N protein 
possesses a very high homology with the SARS- CoV N protein. 
Both contain two structural domains (N- Terminal Domain, NTD 
and C- Terminal Domain, CTD), linked by a non- structured protein 
part. Previous studies revealed that coronavirus N- NTD is the 
RNA- binding domain, while N- CTD is the dimerization domain, 
that also has a certain RNA- binding activity. This plurality of N 
actions makes it a good candidate for therapy. It is to note that, 
although N is an internal viral protein, the presence of IgA, IgM, 
and IgG antibodies against N antigen in the sera of COVID- 19 
infected patients has been reported by immunoblot assays, in-
dicating its importance in host immunity.17 Interestingly, previ-
ous reports (see Ref. [19] and references therein) revealed the 
existence of nuclear localization signals (NLS), especially in the 
CTD part, as well as nuclear export signals (NES) in SARS- CoV 
virus N, suggesting that this RNA- binding protein may serve as a 
dynamic shuttle between the cytoplasm, nucleus, and nucleolus.
Among the multitude of products tested against the 
COVID- 19 disease, a number of natural products have been as-
sayed (critically reviewed in Ref. [20] and references therein), 
targeting mainly the viral proteases in vitro. However, no natu-
ral product has been proposed to target the N protein. Recently, 
we have reported that a combination of three aromatic plants 
(Thymbra capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa 
Mill.,21 and references therein) is efficient against upper respira-
tory tract viral infections. Further in vitro studies revealed that a 
primary target of this preparation is the viral nucleoprotein (NP), 
inhibiting its nuclear translocation,22 and impairing viral protein 
transcription, while a proof- of- concept clinical trial suggests a 
possible action of the preparation in mild, ambulatory, COVID- 19 
positive patients (Lionis et al.23). Based on these data, we have 
analyzed, in silico, the different constituents of our preparation, 
against the SARS- CoV- 2 N protein and other viral NPs (influenza, 
rabies, Ebola). Here, we report that p- cymene, a natural mono-
terpene, at non- toxic concentrations, impairs viral replication. In 
silico molecular simulation and molecular dynamics (MD) studies 
suggest that p- cymene can bind to the CTD part of SARS- CoV- 2 
N protein, as well as to influenza, rabies, Ebola NPs. We further 
report that p- cymene impairs viral infection in vitro. Therefore, 
p- cymene might represent a valid therapy, alone or in combina-
tion with other drugs, in cases of COVID- 19, or other diseases 
caused by RNA- viruses.
Significance Statement
p- cymene inhibits SARS- CoV- 2 and impairs Influenza 
H1N1 viral replication, in vitro, at non- toxic concentra-
tions. This action is exerted by p- cymene interaction with 
SARS- CoV- 2 nucleocapsid and influenza nucleoprotein, as 
revealed by extensive in silico molecular simulation and mo-
lecular dynamics. We propose p- cymene as a possible anti-
viral agent, alone or as an adjuvant therapeutic, in cases of 
COVID- 19, or other diseases caused by RNA- viruses.
p- cymene as a possible antiviral, alone, or in combination with other agents, in a 
broad spectrum of RNA viruses, from SARS- CoV- 2 to influenza A infections.
K E Y W O R D S
Ebola, importin A, influenza A, nucleocapsid protein, nucleoprotein, p- cymene, rabies, 
SARS- CoV- 2
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2  |  MATERIAL AND METHODS
2.1  |  Docking simulations
The sequence of nucleocapsid proteins from SARS- CoV- 2, influenza, 
Ebola and rabies viruses, in fasta format, was retrieved from the 
NCBI protein database (https://www.ncbi.nlm.nih.gov/prote in/) and 
introduced to the GalaxyWeb server (http://galaxy.seokl ab.org/), 
routine TMB.24– 27 For SARS- CoV- 2 CTD, we used a model based on 
the PDB 6WJI crystal,28 while for influenza, rabies and Ebola NP, we 
have relied on the models from the GalaxyWeb, as these proteins 
have not yet been crystalized. p- cymene mol2 file format was pre-
pared by the OpenBabel program (http://openb abel.org).29
Each protein (in pdb format) and ligand (in mol2) files were 
uploaded to the GalaxyWeb server and a fully flexible dock-
ing (involving the receptor and the ligand) was performed, fol-
lowed by optimization and subsequent refinement, through 
the GalaxyRefine algorithm.24,27 The best solution (denoted as 
“Model 1”) was retained. The corresponding pdb file (containing 
the protein– ligand complex) was retrieved. The 3D structures of 
the ligated and unligated N protein were compared and the root 
mean square deviation (RMSD) was calculated by UCSF Chimera 
1.11.2 program.30
The sequence of human coronavirus 229E nucleocapsid protein 
mRNA (GenBank: J04419.1), part of the whole SARS- CoV- 2 mRNA, 
was used as a template, in order to simulate the interaction of SARS- 
CoV- 2 N- protein- viral mRNA. It was introduced to the RNAfold web 
server (http://rna.tbi.univie.ac.at/cgi- bin/RNAWe bSuit e/RNAfo 
ld.cgi) to predict the secondary structure of the single- stranded 
RNA sequence, by using minimum free energy prediction.31 The 
resulting mRNA secondary structure was then introduced to the 
RNAComposer server (http://rnaco mposer.cs.put.poznan.pl/),32,33 a 
fully automated modeling service, which returned a single 3D- RNA 
structure model of the viral mRNA.
For protein– protein and protein– RNA interactions, we have used 
the HEX 8.0.0 program (http://hex.loria.fr/).34
2.2  |  Molecular dynamics
The crystal structure of the SARS- CoV- 2 nucleocapsid protein (C- 
terminal dimerization domain, residues 249– 389, PDB entry: 6WJI28) 
and human importin- α (residues 71– 197) containing the interaction 
site with the NLS sequence of cargo proteins35 were used as initial 
coordinates to build MD models. A nucleocapsid– importin com-
plex was produced based on docking calculations with the HEX34 
program.
The Amber0336 protein force field was used for the residues and 
ions. The Amber03 parameters for p- cymene were derived based on 
the ACPYPE algorithm.37
Classical MD production trajectories were run with the leap- 
frog integrator in GROMACS 202038 for the nucleocapsid– importin 
complex with and without p- cymene. Seven replicas (trajectories) 
were run per sample (with or without p- cymene) starting from seven 
different structures extracted at the equilibration process. The 
equations of motion were integrated for 2.0 μs per replica, in a total 
simulation time of 28 μs. The classical MD trajectories were ana-
lyzed by Markov state modeling (MSM).39– 41 The classical MD runs 
were followed by the multiple walkers (MW) variant of the meta-
dynamics method42 again with seven replicas per sample for 0.7 μs 
each replica, with selected nucleocapsid- importing distances as col-
lective variables to be biased in the enhanced sampling.
Α detailed description of the MD/enhanced sampling implemen-
tation and data analysis are presented in Supporting Information, 
Material and Methods.
2.3  |  Biochemical and cellular methods
2.3.1  |  Cell	culture,	virus	infections,	and	cell	
proliferation analysis
SARS- CoV- 2 (isolate 30– 287) was obtained through culture in 
Vero E6 cells (ATCC® CRL- 1586), from an infected patient, in 
Alexandroupolis, Greece. Virus stock was prepared by infecting fully 
confluent Vero E6 cells in DMEM, 10% fetal bovine serum, with an-
tibiotics, at 37°C, 5% CO2. Four days after inoculation, the super-
natant	was	 frozen	 at	 −80°C	until	 use.	 Infections	were	 carried	out	
in 96- well plates, using SARS- CoV- 2 (m.o.i. of 0.1) on Vero E6 cells. 
Cells were treated with different concentrations of p- cymene, in a 
volume of 15 μl, per 150 μl of medium, for 48 h. Cell morphology was 
observed with phase contrast, in an inverted microscope, to record 
CPE. Culture supernatants were analyzed using real- time RT- PCR.
Madin- Darby Canine Kidney cells (MDCK; ATCC® CCL34™) cells 
were grown according to standard conditions, as described in detail 
in.43 Human influenza virus strain A FM/1/47 (H1N1) was obtained 
from ATCC. Influenza virus strain was studied in MDCK cells in 
serum- free MEM, containing 1 μg/ml trypsin TPCK- treated (Sciex), 
2 mM L- glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomy-
cin. Evaluation of virus titers and viral growth curves were carried, 
according to standard protocols.44 In the present study, we have 
probed different concentrations of p- cymene (up to 2 mg/ml).
Analysis of the effects of p- cymene on the cell viability was per-
formed in MDCK and Vero E6 cells using the tetrazolium MTT assay 
for 24, 48, and 72 h respectively.43
2.3.2  |  Titration	assay
Titration of SARS- CoV- 2 infected cells was carried in 96- well plates, 
using Vero E6 cells and TCID50 was calculated according to the 
method of Reed and Muench45 and by sigmoidal fitting. Plates were 
incubated at 37°C for 4 days, and the cytopathic effect (CPE) was 
scored by observation under an inverted phase- contrast microscope.
The antiviral activity of p- cymene on Influenza A virus was 
assayed in plaque- reduction assay (expressed in the number of 
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forming plaques), with Ribavirin as a positive control (25 μg/ml). 
After 3– 4 days and upon plaque formation, cells were fixed with 
paraformaldehyde and cell monolayers were stained with crystal vi-
olet. Following staining the plaques that developed were counted, 
and the viral titer was evaluated by the formula: X = (# of plaques)/
(d × V) where X = the titer, d = dilution factor and V = the volume of 
diluted virus instilled on the cells, as detailed previously.22
2.3.3  |  Real-	time	quantitative	PCR
To determine the SARS- CoV- 2 viral load, RNA was extracted from 
96- well supernatants (100 μl) using NucleoSpin Dx Virus according 
to the manufacturer (Macherey Nagel). Multi- target real- time RT- 
PCR was performed using COVID- 19 SARS- Cov- 2 Real- TM accord-
ing to the manufacturer (Sacace Biotechnologies).
For influenza experiments, MDCK cells (2 × 105) were plated in 12- 
well plates and after 24- h infected with influenza A FM/1/47/H1N1 or 
HRV14 for 2 h at 37°C. Subsequently, cells were incubated in the ab-
sence (control) or the presence of p- cymene for 12 h. Total RNA was 
extracted with NucleoSpin RNA kit (Macherey- Nagel). The in vitro quan-
tification of influenza A genome was performed using the Techne qPCR 
human influenza A (M1) genome kit (TechneTM), following the manu-
facturer's instructions, in a Stratagene Mx300 P qPCR System. Relative 
expression levels of target genes were calculated from Ct values.
2.3.4  |  Immunofluorescence	analysis
Madin- Darby Canine Kidney cells were plated on glass coverslips 
in 24- well plates. After 24 h, they were infected with influenza A 
FM/1/47/H1N1 for 1 h at 37°C. MEM supplemented or not with p- 
cymene was added, and cells were fixed 6 h after the infection with 
4% PFA and permeabilized with 0.1% TritonX- 100, for 10 min. Cells 
were stained with a mouse monoclonal anti- NP antibody (Santa 
Cruz), followed by a secondary FITC- labeled goat anti- mouse anti-
body (Santa Cruz). The nuclei were stained with DAPI. Fluorescent 
images were acquired with an epifluorescent Leica DMIRE2 micro-
scope equipped with a Leica DFC300FX digital camera.
2.3.5  |  Immunoblot	assays
For the analysis of whole- cell extracts, cells were collected and pel-
leted at 2500 g for 10 min. The M- PER Mammalian Protein Extraction 
Reagent (Cat. No 78503; Thermo Scientific) along with protease in-
hibitors (Cat. No 78415; Thermo Scientific) was used. Samples were 
boiled in SDS gel- loading buffer, separated by electrophoresis and 
transferred on to PVDF membrane. Membrane was blocked with 
TBST buffer with 5% (w/vol) dried non- fat milk and incubated with 
primary antibody of NP (sc- 80481; Santa Cruz). Following incubation 
with the primary antibody, membrane was incubated with second-
ary antibody (goat Anti- mouse IgG Antibody, Peroxidase Conjugated, 
H+L [AP124P] Sigma). The membrane was developed using Luminata 
Forte Western HRP Substrate (Cat. No WBLUF0100; Millipore) by the 
ChemiDoc™ MP System (Cat. No 170- 8280; Bio- Rad).
2.4  |  Statistical analysis
Statistical analysis was performed in GraphPad Prisma V6.05 
(GraphPad Software Inc.) and Origin 2018 (OriginLab Co.), with the 
tests described in Section 3. A threshold of p < .05 was retained for 
significance.
2.5  |  Nomenclature of targets and ligands
Key protein targets in this article are hyperlinked to corresponding 
entries in http://www.guide topha rmaco logy.org, the common portal 
for data from the IUPHAR/BPS Guide to PHARMACOLOGY,46 and 
are permanently archived in the Concise Guide to PHARMACOLOGY 
2019/20.47 The ligand (p- cymene) is hyperlinked to the PubChem 
database (https://pubch em.ncbi.nlm.nih.gov/).
3  |  RESULTS
3.1  |  In silico simulation reveals that p- cymene 
interacts with the Importin- binding domain of SARS- 
CoV- 2 N protein and impairs its association with the 
IMPα- IMPβ- RanGDP complex
Nucleocapsid SARS- CoV- 2 is a large protein of 419 amino acids (NCBI 
Reference Sequence: YP_009724397.2). Until today, the crystal struc-
ture of the complete protein has not been resolved. By contrast, a 
number of crystals (PDB codes 6M3M, 6VYO, 6YI3) of the N- , RNA- 
binding, terminal part, and the C- dimerization part of the protein (PDB 
code 6WJI) have been reported (Figure S1). Previous reports suggest 
that SARS- CoV N protein (90% homolog to SARS- CoV- 2) may quickly 
shuttle between the nucleus and the cytoplasm, a process regulated 
by N protein phosphorylation,48 while the transfer of the viral RNA to 
the nucleus has also been suggested.19 Therefore, we have scanned 
the SARS- CoV- 2 N protein for the existence of the prototype NLSα se-
quence PRQKRTATKAY.35 It was identified in position 258– 268 of the 
N protein, within its structured C- terminal part (Figure 1A). Simulation 
of N binding with the complex IMPα- IMPβ- RanGDP and viral RNA (see 
Ref. [35] for methodological details) (Figure 1B) confirmed the high- 
affinity binding of Importin complex to N (ΔG	−1000.5	kcal/mol	 for	
importins	and	−418.7	kcal/mol	for	RNA,	localized	at	the	structured	N-	
terminal part of the protein, Figure 1B).
Molecular docking simulation of the p- cymene binding on SARS- 
CoV- 2 N protein revealed a high- affinity association of the ligand 
in the structured C- terminal part of the molecule (ΔG	=	−5.6	kcal/
mol, corresponding to an apparent affinity of 113 μΜ). p- Cymene 
binds within the NLS sequence of the protein (Figure 1C) and 
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interacts with amino acids Arg262 and Thr265. This interaction in-
duces a significant conformational change of the NLS region of the 
N protein (RMSD = 1.708 Å), resulting in a re- orientation of amino 
acids Arg262 (RMSD = 2.801 Å), Lys266 (RMSD = 2.759 Å), and Glu260 
(RMSD = 2.650 Å) of the NLSα sequence (Figure 1C). These changes 
impair the interaction of N with the IMPα- IMPβ- RanGDP complex. 
As expected, viral RNA- binding interaction with N protein remains 
unaltered (ΔG	=	−418.7	kcal/mol	in	the	absence	and	−453.4	kcal/mol	
in the presence of p- cymene).
Molecular dynamics simulations of N protein complex with 
Importin A, in the absence or the presence of p- cymene (Figure 2), 
revealed that p- cymene is able to destabilize the nucleocapsid– 
importin complex. The Free Energy Surfaces for the dissociation of 
the nucleocapsid– Importin complex in the absence or the presence 
of p- cymene respectively are reported herein. Two main minima 
are observed (M1, M2). The transition from M1 to M2 and beyond 
(larger distances and complex radii of Gyration) is happening on 
a shallower energy surface in the presence of p- cymene, com-
pared with its absence, and a reduced energy barrier, suggestive 
of a weaker association of Importin A with N protein in the former 
case, verifying molecular docking data. The structures of the two 
complexes, at minima M1 and M2, are also given for reference. The 
F I G U R E  1 (A)	Sequence	of	the	SARS-	CoV-	2	N	protein.	In	purple	are	shown	the	crystalized	parts	of	the	protein,	while	in	green	is	
presented the nuclear localization signal (NLS) sequence. (B) In silico simulation of the binding of the IMPα- IMPβ- RanGDP complex and viral 
RNA with SARS- CoV- 2 N protein. ΔG for the interaction of N protein with the IMPα- IMPβ- RanGDP complex and with viral RNA are also 
shown. (C) Docking of p- cymene within the NLS sequence of N protein shown in yellow. As shown the ligand interacts preferentially with 
Arginine 262 and Threonine 265 at the center of the NLS sequence (aa 258– 268), therefore impairing the interaction of N with importins
F I G U R E  2 Free	energy	surfaces	for	the	dissociation	of	the	nucleocapsid–	Importin	α complex in the absence (A) and the presence of p- 
cymene (B). (C) The associated structures at the M1– M2 minima of the complex
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MSM analysis of the classical MD trajectories has indicated several 
important residues of the nucleocapsid protein that are involved 
in the dynamics of its interaction with importins (see Supporting 
Information). Interestingly enough, ten out of the most important 
residues of the SARS- CoV- 2 N protein (83, 193, 256, 276, 280, 361, 
369, 370, 374, 387) are associated with the formation of salt bridges 
between nucleocapsid and Importin- α in the absence of p- cymene. 
To the contrary, only five out of the most important residues of the 
nucleocapsid protein (193, 259, 276, 280, 361) are associated with 
the formation of salt bridges between nucleocapsid and Importin- α 
in the presence of p- cymene. This definitely indicates a weaken-
ing of the nucleocapsid– Importin- A association in the presence of 
p- cymene.
Previous reports suggest that SARS- CoV- 2 protein dimerizes 
through an interaction of its N- CTD η1 domain.49 p- Cymene is 
predicted to bind at this region (amino acids Arg262 and Thr265), 
impairing the antiparallel dimer formation of the N- CTD protein 
(Figure S2).
3.2  |  p- Cymene is predicted to bind to the NLS- 
domain of a number of other viral NP proteins and 
impairs importin binding
A number of RNA viruses contain NPs, which may shuttle be-
tween the cytoplasm to the nucleus. This transfer depends also on 
the binding of NPs to host importins and the subsequent nuclear 
internalization, through nuclear pores. Here, we confirmed the 
presence of a NLS for Importin α (NLSα, Figure 3A) in a number of 
RNA viruses (Influenza A, Rabies, Ebola), employing the aforemen-
tioned methodology. p- Cymene docking simulation on these NPs 
revealed an interaction within their NLS region. In detail, p- cymene 
interacted with Influenza A NP at the region 169– 177, with Rabies 
NP at the regions 241– 250, 312– 315, and 322– 325 and with Ebola 
NP at the regions 162– 163, 204– 211, and 299– 300 (Figure 3B– D). 
Interestingly, binding of p- cymene to the specific proteins inhibits 
(Influenza H1N1 and Ebola) or impairs significantly (Rabies) the in-
teraction of NP with Importin α (Figure 3E).
p- Cymene interacted with Influenza A (H1N1) NP through bind-
ing with Thr177, the first of amino acid of NLS of this NP (Figure S3). 
This binding induced a significant conformational change of the 
NLS region of the protein (1.252 Å). In addition, as shown in 
Figure S4A, the orientation of Arg180 and Arg181, necessary for im-
portin recognition, is significantly modified after p- cymene binding 
(RMSDARG180 = 2.969 Å and RMSDARG181 = 1.831 Å), by adopting a 
reversion of their orientation axis, hiding the NLS sequence from 
the importin complex. A similar change of the orientation of NLSα 
amino acids occured in rabies NP (RMSD of the NLS region after 
p- cymene binding = 2.090 Å). In addition, significant conformational 
changes of the amino acids Arg418 and Arg423 (RMSD changes after 
p- cymene binding = 2.043 and 3.576 Å respectively, Figure S4B) 
occured after p- cymene binding. These conformational changes 
resulted in a significant modification of the NLSα region, partially 
impairing the binding of Importin A and subsequently the efficient 
F I G U R E  3 (A)	Comparison	of	nuclear	localization	signal	(NLS)	sequences	in	Influenza	H1N1,	Ebola,	Rabies,	and	SARS-	CoV-	2	viruses.	(B–	
D) Simulation binding of p- cymene (red color) on Influenza H1N1, Rabies, and Ebola nucleoproteins (NPs). The NLS sequence of each protein 
is presented in blue color. (E) Table summarizing the RNA and Importin binding to Influenza H1N1, Rabies, and Ebola NPs in the absence or 
the presence of p- cymene
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nuclear translocation of the NP. Finally, p- cymene binds to the 
Ebola NP (Figure 2D; Figure S4C). In particular, p- cymene binded 
to Leu299 and Leu300, two amino acids of the NLS of this NP. The 
RMSD of Ebola NP NLSα increases by 1.041 Å after p- cymene bind-
ing due mainly to Lys281 and Arginine 298 conformational changes (t 
RMSDLYS281 = 1.591 Å and RMSDARG298 = 1.609 Å, after p- cymene 
binding, respectively). These key amino acids for importin recogni-
tion rotated by almost 180°, and impair the recognition of the NLS 
sequence from the importin complex.
3.3  |  In vitro validation of the inhibitory effect of 
p- cymene on SARS- CoV- 2 and Influenza viruses
3.3.1  |  SARS-	CoV-	2
Treatment of SARS- CoV- 2 infected Vero cells with variable concen-
trations of p- cymene resulted in a significant decrease of plaque for-
mation (Figure 4A) and viral titer in the culture supernatants (up to 
90%, verified by Q- PCR), at concentrations ranging from 0.0125 to 
200 μg/ml, after 2 days of incubation (Figure 4). Up to 95% reduced 
titer was also observed during pre- treatment of Vero cells, by Q- 
PCR, prior to infection with SARS- CoV- 2 (Figure 4B). The IC50 during 
co- treatment was 74.5 μg/ml, while pre- treatment IC50 was reduced 
to 57 μg/ml, as calculated by sigmoidal fitting of data. Importantly, 
p- cymene at concentrations <100 μg/ml does not impair cell viability 
(Figure S5).
3.3.2  |  Influenza	A	(H1N1)
Incubation of MDCK cells with variable concentrations of p- cymene 
for 72 h revealed a modest effect of plaque formation, much 
lower than that of ribavirin (25 μg/ml), used as a positive control 
(Figure 5A). However, p- cymene (20 μg/ml, as higher concentrations 
induced a decreased cell viability, Figure S5) significantly decreased 
the production of progeny virus (Figure 5B), and also decreased the 
genomic expression of viral proteins, as shown in Figure 5C for M1 
matrix protein genome, assayed by Q- PCR and the expression of in-
fluenza NP protein levels (Figure 5D). Finally, in view of our in silico 
data on the impairment of Importin A binding and the subsequent 
reduction of viral RNA transport to the nucleus, we assayed by im-
munofluorescence the cellular distribution of influenza NP. As shown 
in Figure 5E, after a 6 h incubation of infected cells with 20 μg/ml of 
p- cymene, a reduced number of NP- positive stained cells and a de-
crease of nuclear translocation of NP were found.
4  |  DISCUSSION
COVID- 19 pandemics imposed a number of, not yet resolved, prob-
lems to the scientific community. In spite of the combined world- 
wide scientific effort and the analysis of SARS- CoV- 2 virus,1 neither 
a prophylactic or therapeutic regimen has been proposed, with the 
exception of monoclonal antibodies8,9 and dexamethasone,50,51 
which target hospitalized patients, in intensive care units. In this 
F I G U R E  4 (A)	Phase-	contrast	photographs	of	cells	infected	with	SARS-	CoV-	2	and	co-	treated	or	pre-	treated	for	2	h	with	the	indicated	
concentrations of p- cymene. (B) The inhibition of SARS- CoV- 2 RNA in the supernatant of cell cultures is presented (mean ± SD) of cells 
co- treated or pre- treated for 2 h with the indicated concentrations of p- cymene together with a sigmoidal fit of data. The obtained IC50s are 
also presented
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respect, the search of small, non- expensive molecules, efficient 
in non- critically- ill patients, remains unmet. In this line, repurpos-
ing existing drugs against known or predicted SARS- CoV- 2 protein 
actions have been documented (reviewed and discussed in Refs 
[52– 54]), while natural products have also been tested (reviewed in 
Ref. [20]). Finally, quercetin has been proposed as an alternative for 
dexamethasone.55
Here, we propose that p- cymene can act as a potential novel 
agent for the treatment of RNA viruses- induced diseases (influenza, 
rabies, Ebola), including SARS- CoV- 2- induced COVID- 19. In addition, 
our preliminary in vitro studies showed that the effect of p- cymene is 
exerted at the low micromolar range, an effect compatible with our 
simulation data and the reported change in Gibbs free energy (ΔG 
−5.6	kcal/mol	for	p-	cymene	interaction	with	SARS-	CoV-	2	N	protein,	
and	−6.5,	−5.5,	and	−4.3	kcal/mol	for	influenza	A,	rabies,	and	Ebola	
NPs respectively). In addition, the decrease of the transcripts and 
the protein content of key viral proteins provides further evidence 
for the validity of the proposed mechanism. We further suggest as 
a possible mechanism of action its interaction with SARS- CoV- 2 N- 
protein and viral NPs, impairing their cytoplasmic- nuclear shuttle, 
supported by extensive molecular docking and MD studies.
Our results on SARS- CoV- 2 were performed in the African green 
monkey kidney Vero E6 cell line. These cells are the standard cell line 
used for SARS- CoV and SARS- CoV- 2 antiviral screening, as they are 
highly permissive to virus infections and lack interferon production 
allowing for CPE observation. However, resent studies 56– 59 suggest 
that both infection and therapeutic responses might be cell line- 
dependent. Indeed, in an exhaustive study59 it was reported that 
only few human cell lines (CaCo- 2, Huh7, 293T, and Calu- 3), derived 
from colorectal adenocarcinoma, hepatocellular carcinoma, embry-
onic kidney, and lung adenocarcinoma respectively, were suscepti-
ble to SARS- CoV- 2 infection, together with a number of other animal 
cell lines. Interestingly, the susceptibility for SARS- CoV- 2 infection 
was not observed in other cell lines from the same anatomical site. 
As pulmonary infections are one of the primary sites of SARS- CoV- 2 
symptom manifestation, Calu- 3 cells were also extensively used for 
drug screening,56– 58 with the authors suggesting that evaluation of 
novel antiviral candidate drugs should be performed in different cell 
lines to exclude potential cell- dependent artefacts. Interestingly, en-
dosomal acidification was required for SARS- CoV- 2 entry to main-
tain the low pH necessary for endosomal cysteine protease activity, 
required for priming Spike for membrane fusion in Vero and Huh7.5, 
F I G U R E  5 (A)	Plaque	reduction	assay	of	Madin-	Darby	Canine	Kidney	(MDCK)	cells	infected	with	Influenza	H1N1	virus	(0.05	PFU/cell)	
and incubated with variable concentrations of p- cymene for 72 h. Figure shows mean ± SD of two experiments in triplicates. Ribavirin 
(red dot) at 25 μg/ml is presented as a positive control. *p < .05 as compared to non- treated cells. (B) p- cymene reduces the production of 
progeny virus, as assayed by quantitative PCR of the supernatants of MDCK cells were pretreated with p- cymene (20 μg/ml) and infected 
with influenza A/H1N1 virus (0.1 PFU per cell) for 24 h. (C) Quantification by qRT- PCR of FluA M1 genome copies in MDCK cells infected 
with FluA/H1N1 at MOI 0.5 PFU/cell. Data shown are means ± SD of two independent experiments. (D) Immunoblot analysis of influenza 
nucleoprotein (NP) in total MDCK cell lysates incubated for 10 and 24 h post- infection with variable concentrations of p- cymene. (E) The 
role of p- cymene in the NP distribution. MDCK cells were infected with FluA/H1N1 (MOI 5) in the absence or presence of p- cymene. Six 
hours after the infection, cells were fixed and subsequently stained using influenza A anti- NP primary antibody followed by FITC secondary 
antibody (green). DAPI was used to visualize the nucleus area (blue)
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while the plasma membrane- associated serine protease TMPRSS2 is 
necessary for the viral glycoprotein entry priming in lung epithelial 
cells.60 Although, here, we have not assayed the response of other 
cell lines to p- cymene, the proposed mechanism of action (binding 
to the SARS- CoV- 2 N protein, modifying its trafficking and action) 
is beyond differences in viral entry mechanisms. However, a thor-
ough determination of p- cymene effect in a number of SARS- CoV- 2 
human and animal cell lines is required, before its proposed use as a 
possible drug.
In contrast to SARS- CoV- 2 infected cells, the effect of p- cymene 
did not induce a complete elimination of influenza viral infection, 
at non- toxic concentrations, suggesting that, this agent should 
be used in combination with other anti- viral compounds. A previ-
ous study22 revealed that a combination of plant essential oils, in 
which p- cymene is a major constituent,61 is by far more potent in 
inhibiting Influenza A (as well as Influenza B and rhinovirus RSV14) 
strains. Interestingly, molecular docking of all major constituents on 
Influenza A NP revealed that the majority of constituents bind at the 
same groove as p- cymene (Figure S6), suggesting an additive action 
of the different compounds.
p- Cymene is a naturally occurring organic compound that is 
classified as a hydrocarbon, related to a monoterpene. p- Cymene 
is an isoprenoid lipid molecule with one aromatic ring. It exists as 
a solid and is considered to be practically insoluble in water, with a 
molecular weight of 134.222 g/mol, water solubility 23.4 mg/L and 
boiling point 177.1°C. It is a constituent of the essential oils of more 
than 100 plant species, such a T. vulgaris and O. vulgare subsp glan-
dulosum.62,63 According to the Code of Federal Regulations of the 
U.S. Food and Drug Administration (21CFR172.515) it is considered 
to be “Generally Recognized As Safe” and the EU (REACH, docu-
ment Proposal for Harmonized classification and Labeling based on 
Regulation EC No 1272/2008, Annex VI, Part 2, Substance Name: 
1- isopropyl- 4- methylbenzene; ρ- cymene). A search in Pub- Chem re-
vealed that the in vitro IC50 of the agent is >1 mg/L tested in human 
monocytes,64 while its LD50 is 1125 mg/kg IP and 1695 mg/kg PO 
(https://pubch em.ncbi.nlm.nih.gov/compo und/7463#secti on=Tox-
icity), much higher than the concentration impairing viral prolifera-
tion VERO E6 (50– 70 μg/ml) or MDCK cells (20 μg/ml), reported here. 
In humans, p- cymene, at doses >3 g/kg induced only mild gastroin-
testinal symptoms (nausea, vomiting) or headache. The properties 
of p- cymene in humans have been recently reviewed.65 According 
to the authors (and references therein), p- cymene possesses anti-
bacterial, antifungal, and antiparasitic activities, combined with anti- 
inflammatory actions. However, as the authors discuss, p- cymene is 
not the main constituent in natural extracts, responsible for these 
actions, but it might act through synergism, antagonism, or additive 
effects. Here, we extend these actions, by reporting a proper anti-
viral effect, and suggest, by in silico studies, a novel mechanism of 
action through binding to NPs, including the nucleocapsid (N) pro-
tein of SARS- CoV- 2, impairing the protein cytoplasmic- nuclear shut-
tle. It derives that p- cymene can be used as a safe agent in cases 
of COVID- 19 positive patients, at the concentrations revealed from 
our study.
SARS- CoV- 2 N protein is mainly cytoplasmic, with very rare 
reports suggesting a possible nuclear translocation. This 46- kDa 
protein presents a ~90% homology to the SARS- CoV N, and a 
major factor conferring the enhanced pathogenicity of SARS- 
CoV- 2.66 N represents the most abundant SARS- CoV- 2 protein in 
the infected cell,67– 69 while anti- N SARS- CoV- 2 antibodies are the 
main humoral response of COVID- 19 patients.70 The N protein is 
the central component of SARS- CoV- 2 virions. It forms the viral 
ribonucleoprotein (RNP) complex through binding to viral RNA; 
it has a primary role in viral mRNA transcription and replication, 
cytoskeleton organization, and immune regulation. In addition, 
it functions as a suppressor of cellular RNA transcription (Ref. 
[18] and references herein). Interestingly, SARS- CoV- 2 has spe-
cific nuclear localization (NLS), as also reported here, and NES,71 
suggesting a possible cytoplasmic- nuclear shuttle. However, in 
our analysis only one NLSα is found, contrasting the three NLSα 
signals reported previously.71 SARS- CoV- 2 N protein is a major 
target of phosphorylation by host cell protein kinases, with 22 
putative phosphorylation sites.68 Simulations performed in this 
work show a possible association of SARS- CoV- 2 N- protein with 
importin α, a process inhibited by p- cymene. In support of such 
a mechanism, previous work has revealed that nuclear SARS- 
CoV N protein (90% homolog to SARS- CoV- 2) shuttles between 
the nucleus and the cytoplasm, a process regulated by N protein 
phosphorylation by several protein kinases, including glycogen 
synthase kinase- 3, protein kinase A, casein kinase II, and cyclin- 
dependent kinase.48 The authors suggest that nuclear localization 
of SARS- CoV N protein is very short, and that the phosphorylated 
protein is very quickly translocated to the cytoplasm after being 
bound to 14- 3- 3 protein isoforms. Interestingly, a very recent 
report has shown a similar interaction of phosphorylated SARS- 
CoV- 2 N protein with all 14- 3- 3 isoforms,72 leading to a similar 
quick nucleo- cytoplasmic shuttling of SARS- CoV- 2 protein. In 
this respect, our data suggesting an interaction of p- cymene with 
SARS- CoV- 2 N protein, impairing its interaction with Importin 
α and subsequently inhibiting its cytoplasmic- nuclear shuttle, 
might represent a valid pharmaceutic intervention in the course 
of COVID- 19 diseased patients.
Interestingly, p- cymene binds also in the vicinity of the NLSα se-
quence of NPs of other RNA viruses (influenza, rabies, and Ebola), 
as revealed by simulation, modifying significantly the 3- D confor-
mation of the NLS site, and inhibiting its interaction with importin 
α, a mechanism known for influenza virus and suggested for Ebola, 
through an alternative O- glycosylation and O- phosphorylation,73 a 
valid mechanism in a number of other proteins.74 Finally, we suggest 
a similar mechanism for the rabies virus, although this should be con-
firmed by in vitro experiments. Therefore, this common mechanism 
of action renders p- cymene as a possible antiviral agent, in a broad 
spectrum of RNA viruses from influenza A to COVID- 19, as verified 
by our in vitro studies of cells infected with influenza or SARS- CoV- 2.
Is therefore p- cymene a potential anti- viral compound? p- 
Cymene's rapid absorption, leading to a time of maximum con-
centration of 0.33 h,75 is in favor of its use. However, p- cymene is 
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also eliminated very rapidly (T1/2 0.44 h) from the plasma, although 
plasma concentration versus time profile of p- cymene shows a 
double- peak which might be due to distribution, reabsorption, or en-
terohepatic circulation.75 Finally, taking into consideration the half- 
life of p- cymene, assuming an absorption of 50% after an oral dose, 
the effective concentration of 20– 50 μg/ml in the interstitial fluid, 
a dose of 12 mg of p- cymene should be administered every 6 h for 
a 70 kg adult, in order to maintain an effective concentration. This 
dose is far below that reported to induce any side effect in animals 
or in humans (https://pubch em.ncbi.nlm.nih.gov/compo und/7463#-
secti on=Toxicity).
In conclusion, data presented in this study suggest that p- 
cymene, a non- toxic natural compound, may be used alone or as 
a companion therapeutic for the control of RNA viral diseases, in-
cluding COVID- 19 and influenza. However, the in silico identified 
mechanism of action should be further verified by additional in vitro 
experiments.
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